Multiple System Atrophy Pipeline Insight 2025: 22+ Pipeline Drugs, Disease-Modifying Candidates, and Symptomatic Therapies Advancing Clinical Care | DelveInsight

DelveInsight's "Multiple System Atrophy (MSA) - Pipeline Insight, 2025" reviews a growing portfolio of 22+ therapies in development for MSA, a rare, rapidly progressive neurodegenerative disorder characterized by autonomic failure, Parkinsonism, and cerebellar dysfunction. With no approved disease-modifying treatments and a high unmet need for therapies that slow progression or meaningfully improve function, MSA remains a critical focus area in movement disorders research.

The MSA pipeline spans disease-modifying strategies (including anti-alpha-synuclein antibodies and small molecules that target protein aggregation), neuroprotective agents aimed at mitochondrial or lysosomal function, and symptomatic therapies addressing autonomic dysfunction, orthostatic hypotension, and motor impairment. Cell- and gene-based approaches, as well as drug-repurposing programs, are also being explored to accelerate development timelines. Biomarker and imaging advances are enabling better patient selection and earlier trial readouts, crucial for a condition with a heterogeneous clinical presentation.

Several programs have progressed into mid-stage studies, reflecting intensified investment and collaborative efforts between biotech, academic centers, and consortia. As trial designs mature and biomarkers improve, the MSA landscape is shifting from supportive care toward targeted, mechanism-based interventions that could alter disease trajectory and patient outcomes.

DelveInsight's Multiple System Atrophy - Pipeline Insight, 2025 provides a concise assessment of clinical candidates, mechanism-of-action trends, and competitive positioning-offering stakeholders actionable intelligence on a pipeline that holds promise to transform care for people living with MSA.

Interested in learning more about the current treatment landscape and the key drivers shaping the multiple system atrophy pipeline? Click here: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Multiple System Atrophy Pipeline Report
• DelveInsight's multiple system atrophy pipeline analysis depicts a strong space with 20+ active players working to develop 25+ pipeline drugs for multiple system atrophy treatment.
• The leading multiple system atrophy companies include Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others are evaluating their lead assets to improve the Multiple System Atrophy treatment landscape.
• Key multiple system atrophy pipeline therapies in various stages of development include Ampreloxetine, ATH434, AB-1005, KM-819, Lu AF82422, CE111BR16, PMN442, and others.
• In September 2025, Teva Pharmaceutical (NYSE:TEVA) announced that its investigational MSA treatment, emrusolmin, received Fast Track designation from the U.S. FDA. The drug is currently in Phase 2 development for Multiple System Atrophy.
• In August 2025, Tiziana Life Sciences received FDA clearance of its IND for a Phase 2a trial of intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved therapies. The six-month open-label study will evaluate microglial activation, clinical outcomes, and safety of the fully human anti-CD3 monoclonal antibody delivered via nasal spray.
• In July 2025, NKGen Biotech received FDA authorization for an Expanded Access Program (EAP) to use its NK cell therapy, troculeucel, in multiple neurodegenerative diseases-including Alzheimer's, Parkinson's, ALS, MSA, PSP, FTD, MS, and Lewy Body Dementia-beyond its current Phase 2a trial in moderate-stage Alzheimer's disease.
• In May 2025, Alterity Therapeutics announced that the FDA granted Fast Track designation for ATH434, its investigational treatment for Multiple System Atrophy (MSA). This designation aims to expedite the development and review of ATH434, recognizing its potential to address the significant unmet need in MSA, a condition currently without an approved therapy.
• In February 2025, Alterity Therapeutics' ATH434 showed promising Phase 2 results in a randomized, double-blind trial for early-stage multiple system atrophy (MSA). The treatment, particularly at a 50 mg dose, was well-tolerated and demonstrated both clinical and biomarker-based benefits.

Request a sample and discover the recent breakthroughs happening in the multiple system atrophy pipeline landscape at https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects the autonomic nervous system and movement. It is characterized by a combination of symptoms, including motor dysfunction, autonomic failure (such as blood pressure issues, bladder problems, and difficulty breathing), and cerebellar ataxia (loss of coordination and balance). MSA is often classified into two subtypes: MSA-P (Parkinsonian type), which resembles Parkinson's disease, and MSA-C (cerebellar type), which affects balance and coordination more prominently. The exact cause of MSA is unknown, but it involves abnormal accumulation of a protein called alpha-synuclein in the brain, leading to cell damage. Symptoms typically worsen over time, and the condition has no known cure. Management focuses on alleviating symptoms and improving quality of life, though treatments for the underlying disease are still under investigation.

Find out more about multiple system atrophy medication at https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multiple System Atrophy Treatment Analysis: Drug Profile
Lu AF82422: H. Lundbeck A/S
Lu AF82422 is a human monoclonal antibody (mAb) designed to target and bind to all major forms of extracellular α-synuclein, thereby preventing its uptake and inhibiting aggregation. The antibody also has an active Fc region, which may enhance immune-mediated clearance of α-syn/mAb complexes via microglia-mediated uptake. Developed by Lundbeck under a joint research and licensing agreement with Genmab A/S, Lu AF82422 is currently being investigated in a Phase III clinical trial for patients with Multiple System Atrophy (MSA).

ATH434: Alterity Therapeutics
ATH434 is an oral therapeutic designed to inhibit the aggregation of pathological proteins involved in neurodegenerative diseases. It works as an iron chaperone, helping restore normal iron balance in the brain, and has demonstrated preclinical efficacy in reducing α-synuclein pathology and preserving neuronal function. ATH434 has shown positive results in Phase I trials, where it was well-tolerated and achieved brain levels similar to those seen in animal models. The drug is currently being studied in two Phase II clinical trials: Study ATH434-201, a randomized, double-blind, placebo-controlled trial in early-stage MSA patients, and Study ATH434-202, an open-label biomarker trial in more advanced MSA patients. ATH434 has received Orphan Drug Designation for MSA from both the US FDA and the European Commission.

Learn more about the novel and emerging multiple system atrophy pipeline therapies at https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Multiple System Atrophy Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Multiple System Atrophy Pipeline Report
• Coverage: Global
• Key Multiple System Atrophy Companies: Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM, Inc., ProMIS Neuroscience, H. Lundbeck A/S, and others.
• Key Multiple System Atrophy Pipeline Therapies: Ampreloxetine, ATH434, AB-1005, KM-819, Lu AF82422, CE111BR16, PMN442, and others.

To dive deep into rich insights for drugs used for multiple system atrophy treatment, visit: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Multiple System Atrophy Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Multiple System Atrophy Pipeline Therapeutics
6. Multiple System Atrophy Pipeline: Late-Stage Products (Phase III)
7. Multiple System Atrophy Pipeline: Mid-Stage Products (Phase II)
8. Multiple System Atrophy Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.